These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35012777)

  • 1. Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents.
    June Choe Y; Yi S; Hwang I; Kim J; Park YJ; Cho E; Jo M; Lee H; Hwa Choi E
    Vaccine; 2022 Jan; 40(5):691-694. PubMed ID: 35012777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
    Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
    JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort.
    Goldin S; Adler L; Azuri J; Mendel L; Haviv S; Maimon N
    Gerontology; 2022; 68(12):1350-1357. PubMed ID: 35134810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
    Barda N; Dagan N; Ben-Shlomo Y; Kepten E; Waxman J; Ohana R; Hernán MA; Lipsitch M; Kohane I; Netzer D; Reis BY; Balicer RD
    N Engl J Med; 2021 Sep; 385(12):1078-1090. PubMed ID: 34432976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022.
    Block JP; Boehmer TK; Forrest CB; Carton TW; Lee GM; Ajani UA; Christakis DA; Cowell LG; Draper C; Ghildayal N; Harris AM; Kappelman MD; Ko JY; Mayer KH; Nagavedu K; Oster ME; Paranjape A; Puro J; Ritchey MD; Shay DK; Thacker D; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(14):517-523. PubMed ID: 35389977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
    Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
    BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
    Fowlkes AL; Yoon SK; Lutrick K; Gwynn L; Burns J; Grant L; Phillips AL; Ellingson K; Ferraris MV; LeClair LB; Mathenge C; Yoo YM; Thiese MS; Gerald LB; Solle NS; Jeddy Z; Odame-Bamfo L; Mak J; Hegmann KT; Gerald JK; Ochoa JS; Berry M; Rose S; Lamberte JM; Madhivanan P; Pubillones FA; Rai RP; Dunnigan K; Jones JT; Krupp K; Edwards LJ; Bedrick EJ; Sokol BE; Lowe A; McLeland-Wieser H; Jovel KS; Fleary DE; Khan SM; Poe B; Hollister J; Lopez J; Rivers P; Beitel S; Tyner HL; Naleway AL; Olsho LEW; Caban-Martinez AJ; Burgess JL; Thompson MG; Gaglani M
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(11):422-428. PubMed ID: 35298453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
    Gazit S; Shlezinger R; Perez G; Lotan R; Peretz A; Ben-Tov A; Herzel E; Alapi H; Cohen D; Muhsen K; Chodick G; Patalon T
    Ann Intern Med; 2022 May; 175(5):674-681. PubMed ID: 35157493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
    Kim HK; Park SK; Choe SA; Gwak ES; Cowling BJ; Kim YM; Lee KH; Lee SW; Kwon GY; Jang EJ; Kim RK; Choe YJ; Kwon D
    Vaccine; 2024 Mar; 42(7):1440-1444. PubMed ID: 38365479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19.
    Hammerman A; Sergienko R; Friger M; Beckenstein T; Peretz A; Netzer D; Yaron S; Arbel R
    N Engl J Med; 2022 Mar; 386(13):1221-1229. PubMed ID: 35172072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experience.
    Sánchez-Zapardiel E; Alós M; Nozal P; González-Muñoz M; Frauca-Remacha E; Gavilán LB; Quiles MJ; Hierro L; López-Granados E
    Front Immunol; 2022; 13():1049188. PubMed ID: 36505469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study.
    Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R
    Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.